Meeting
2021 ASCO Annual Meeting
Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced lung cancer or melanoma.
Authors
Laura A Petrillo
Massachusetts General Hospital and Harvard Medical School, Boston, MA
Laura A Petrillo , Ashley Zhou , Ryan J. Sullivan , Angelo E. Volandes , Joseph A. Greer , Jennifer S. Temel , Areej El-Jawahri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Quality Improvement
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6579)
DOI
10.1200/JCO.2021.39.15_suppl.6579
Abstract #
6579
Poster Bd #
Online Only
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2024 ASCO Annual Meeting
Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in preclinical melanoma models.
First Author: Vincenzo Quagliariello
Poster
2023 ASCO Quality Care Symposium
Addressing barriers in care management, shared decision-making alignment, and educational needs on novel immunotherapy combinations in melanoma.
First Author: Tariqa Ackbarali
Poster
2023 ASCO Quality Care Symposium
Learning about and living with toxicity: A qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers.
First Author: Ayo Samuel Falade
Poster
2022 ASCO Annual Meeting
Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.
First Author: Brian Gastman